Drawing for Y YBG YOUTH BIO GLOBAL

USPTO serial 79370268

Y YBG YOUTH BIO GLOBAL

Reviewed by CopyMark Law Group

Reg. 7464584Status 700Registered
Filing date
Status date
Registration date
Aug 6, 2024
Examiner
HUDSON, TAMARA BREE
Law office
FILE REPOSITORY (FRANCONIA)

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with Y YBG YOUTH BIO GLOBAL?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Gordon E.R. Troy, Esq.

Gordon E.R. Troy, Esq. Gordon E.R. Troy, PCPO Box 67Windsor, VT 05089United States

Goods and services

ClassDescriptionStatusFirst use
003Anti-aging cosmetic preparations; make-up; body and beauty care cosmetics; sun block preparations being cosmetics; non-medicated toiletry preparations; skin cleansers; aromatics in the nature of essential oils; non-medicated soaps for personal use; toothpaste; cosmetic facial packs; perfume; cosmeticsACTIVE—
005Pharmaceutical agents affecting sensory organs for the treatment of wounds, ischemic vascular diseases, stem cells, bacterial infection, cancer; pharmaceutical preparations for health care for the treatment of wounds, ischemic vascular diseases, stem cells, bacterial infection, cancer; pharmaceutical agents affecting peripheral nervous system for the treatment of wounds, ischemic vascular diseases, stem cells, bacterial infection, cancer; dietetic supplements consisting of vitamins, minerals, amino acids and trace elements; dietary supplements; nutraceuticals for use as dietary supplements; biopharmaceuticals for the treatment of cancer; nutritional supplements; probiotic preparations for medical purposes to help maintain a natural balance of flora in the digestive system; gene therapy products, namely, living tissue for transplant purposes and cytostatic for medical purposes; medicines for human purposes for the treatment of wounds, ischemic vascular diseases, stem cells, bacterial infection, cancer; multivitamin preparations; nutraceutical preparations for therapeutic or medical purposes for the treatment of wounds, ischemic vascular diseases, stem cells, bacterial infection, cancer; probiotic supplementsACTIVE—
010Medical instruments for interstitial thermotherapy of biological tissue; medical apparatus and instruments, namely, containers for transporting samples containing living human cells; apparatus for the regeneration of stem cells for medical purposes; genetic testing apparatus for medical purposes; apparatus for use in medical analysis, namely, instrument for cartilage restoration, medical cell sampling instrument, cell testing and cell culture instruments; medical apparatus, namely, interstitial thermotherapy of biological tissue, DNA and RNA testing instrument; diagnostic apparatus for medical purposes for the detection of vascular diseases, cancerACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Feb 15, 2025FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Jan 30, 2025FICSFINAL DISPOSITION NOTICE SENT TO IB—
Jan 30, 2025FIMPFINAL DISPOSITION PROCESSED—
Nov 6, 2024FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Aug 6, 2024NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Aug 6, 2024R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
May 21, 2024NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
May 21, 2024PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
May 1, 2024NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Apr 16, 2024CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Apr 12, 2024TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Apr 12, 2024CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Apr 12, 2024TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Feb 27, 2024RFNTREFUSAL PROCESSED BY IB—
Feb 6, 2024RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Feb 6, 2024RFRRREFUSAL PROCESSED BY MPU—
Jan 20, 2024RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Jan 19, 2024CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 18, 2024DOCKASSIGNED TO EXAMINER—
May 30, 2023MAFRAPPLICATION FILING RECEIPT MAILED—
May 26, 2023NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
May 25, 2023REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance